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BiosafetyAbstract The ultimate goal of synthetic biology is to build customized cells or organisms to meet
specific industrial or medical needs. The most important part of the customized cell is a synthetic
genome. Advanced genomic writing technologies are required to build such an artificial genome.
Recently, the partially-completed synthetic yeast genome project represents a milestone in this field.
In this mini review, we briefly introduce the techniques for de novo genome synthesis and genome
editing. Furthermore, we summarize recent research progresses and highlight several applications
in the synthetic genome field. Finally, we discuss current challenges and future prospects.Introduction
Biologists have long been focusing on understanding the natu-
ral biological processes and mechanisms. Lots of fundamental
questions await to be answered, e.g., how the genome regulates
the entire cellular metabolic network and how unicellular
organisms evolve into multicellular organisms. In this sense,
one of the core questions for the conventional biological stud-
ies is how the phenotypic features of a specific organism are
controlled by its genome (Figure 1). Synthetic biology, onnces and
Figure 1 Relation between traditional biology and synthetic biology
Traditional biological studies aim to understand how genes in a specific genome control different cellular processes such as metabolisms.
In contrast, synthetic biology involves in the design and synthesis of an artificial genome with the aim to build a cell from scratch with
designed functions. The yellow rectangles with rounded corners represent the cell membrane. This cell contains a variety of metabolic
pathways like those depicted in green, blue, yellow, and red, respectively. In the pathways shown, the circle represents the metabolite, the
rectangle represents a specific enzyme, and the arrow represents the direction of the enzymatic reaction.
Wang Y et al / Progress of Genome Writing 11the other hand, takes an entirely new direction to address this
question by adopting a reverse approach: modify or de novo
synthesize an organism’s genome in order to enable designed
biological features. As Richard Feynman once said, ‘‘What I
cannot create, I do not understand”. The ultimate goal of syn-
thetic biology is to build a living cell or an organism with
designed functions (Figure 1) [1]. The success of synthetic biol-
ogy, in a large part, relies on a customized artificial genome.
Genome writing is to build such a customized genome accord-
ing to people’s designs. Currently, several de novo synthetic
genome projects are underway [2]. In parallel, in addition to
building a genome from scratch, synthetic biology also
involves the development of new technologies to control or
modify existing biological metabolisms and processes [3,4].
These engineered organisms or cells can be used for the pro-
duction of pharmaceuticals, chemical compounds, biofuels,
food, and so on.
In general, synthetic biology can be roughly divided into
two subareas [5]: (1) de novo synthesis of an organism, such
as designing and building a synthetic cell with an artificial gen-
ome from scratch; (2) re-engineering an existing organism,
such as engineering metabolic pathways or constructing
genetic circuits to achieve pre-designed functions in the target
organism. Metabolic engineering can alter intrinsic metabolic
pathways of an organism and/or add new metabolic pathways.
Implementation of complex genetic circuits enables newly-
designed functions within the target organism. In order to
achieve these goals, genome writing technologies with different
scales and complexities are needed. Genome writing can be
achieved by de novo genome synthesis technology and genome
editing technology [5]. De novo genome synthesis technologies
are better suited for re-writing large-scale genomes with high
complexity, whereas genome editing technologies are suitable
for small-scale writing tasks on the limited genome loci. In this
review, we mainly focus on genome writing by detailing rele-
vant techniques and briefly summarize recent progresses andpossible industrial applications. Finally, we elaborate on the
current challenges and future directions.
Genome writing is achieved through DNA synthesis
and genome editing
De novo synthesis and assembly technologies
De novo genome synthesis typically starts with assembly of
synthetic single-stranded DNA oligos. These oligos can be
annealed followed by PCR amplification to get the lowest
dimension of double-stranded DNA fragments, which are usu-
ally less than 2 kilobases (Kb) in length. A complete artificial
synthetic genome can then be obtained through stepwise
DNA assembly. The assembly process is achieved at four
scales: Kb-scale assembly, megabase (Mb)-scale assembly,
chromosome-scale assembly, and genome-scale assembly.
Gibson assembly and Golden Gate assembly can be used
for the Kb-scale assembly. The principle of Gibson assembly
is similar to the process of homologous recombination, which
is suitable for assembly of regular sequences but not highly-
repetitive sequences. Gibson assembly is usually capable of
piecing together up to five DNA fragments [6]. Golden Gate
assembly uses a type IIS restriction enzyme based, restric-
tion–ligation combined system for DNA assembly, which is
suitable for all types of sequences including highly-repetitive
ones, and usually up to nine DNA fragments can be assembled
at one time [7]. One limitation of Golden Gate assembly is that
it does not work when there are same type IIS restriction
enzyme sites within the DNA fragments to be assembled.
Mb-scale assembly relies on the use of bacteria or yeast
cells. Pre-assembled Kb-scale DNA fragments need to be
transformed into these cells for a higher level of assembly.
After several rounds of assembly, large DNA fragments in
the range of a few hundred Kb to several Mb can be obtained.
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fragment, such as the switching auxotrophies progressively
for integration (SwAP-In) [8].
Chromosome-scale assembly starts with pre-assembled
large DNA fragments, e.g., Mb-scale DNA donor. Usually,
Mb-scale DNA fragments can be maintained as a yeast
artificial chromosome within yeast cells. To complete the
assembly, the donor yeast cell is typically fused with the host
cell [9].
Genome-scale assembly can be accomplished by mating or
microcell-mediated chromosome transfer (MMCT) [10].
Through chemically-induced micronucleation, artificial chro-
mosomes are packaged with nuclear membrane to produce
micronuclei. Cytoskeleton within the micronuclei is then disar-
ranged by inhibitor to produce microcells containing separated
chromosomes. After a microcell–host cell fusion, the artificial
chromosome can be combined with the host genome [10].
Genome editing technologies
In most cases, a de novo synthesized genome is not needed.
Albeit on a much smaller scale, genetic manipulation of exist-
ing genomes via genome engineering is often sufficient. Tar-
geted genome editing is typically achieved following two
steps [11]. First, engineered endonucleases are used to make
DNA double-stranded breaks (DSB) at the specific sites in
the genome. As a consequence, intrinsic cellular DNA damage
repair (DDR) pathways are activated to repair the DSBs and
sometimes introduce insertions and/or deletions (InDels) at
the target sites. To date, several types of endonucleases have
been exploited, including zinc finger nucleases (ZFNs), tran-
scription activator-like effector nucleases (TALENs), and clus-
tered regularly-interspaced short palindromic repeats
(CRISPR)/CRISPR-associated protein (Cas) systems, among
others [12]. They all have a high degree of targeting flexibility
and can efficiently make DSBs in targeted genome loci.
Regardless, there are significant differences among these three
systems. ZFNs and TALENs are engineered proteins that tar-
get specific DNA sequences through protein-DNA interaction.
As a result, ZFNs and TALENs are usually difficult to design
and construct. In contrast, the CRISPR/Cas system relies on
the simple design and synthesis of an RNA molecule comple-
mentary to the DNA target sites.
There are two main mechanisms for DSB repair, i.e., non-
homologous end joining (NHEJ) and homology-directed
repair (HDR) [13]. NHEJ repair does not require a donor
DNA, and often InDels are introduced at the target sites.
HDR requires a donor DNA to facilitate precise genome mod-
ification at the cleavage sites. In addition, repurposing of engi-
neered nucleases can also enable inactivation of their
endonuclease activity while retaining the DNA binding capa-
bilities. When fused with functional moieties, e.g., epigenetic
modification enzymes, these tools can be harnessed for
epigenetic modification at target genome sites [14,15]. As
another example, when fused with a base editor, these tools
can covert a specific nucleotide to another without introducing
a DSB [16].
Combining de novo genome synthesis and genome engineer-
ing may constitute a superior approach for assembling a large
artificial genome. For example, existing genome can be edited
first and then used as the starting material for de novo genomeassembly. Furthermore, available genome editing tools may
facilitate the integration of large DNA fragments.Genome writing project further human understanding
of biological processes
Understand gene essentiality
Undoubtedly, the most ambitious genome-writing project is
the generation of a synthetic cell with a functional synthetic
genome. The need to design an artificial genome leads to a fun-
damental question: what is gene essentiality? Cellular path-
ways are either essential or non-essential [17]. Essential
pathways are mostly tasked with basic and fundamental cellu-
lar functions that support cell/organism viability, whereas non-
essential pathways are often cell or species-specific. In order to
adapt to the external environment, cellular metabolic path-
ways undergo extensive evolutions, resulting in the develop-
ment of a series of complex secondary metabolic
mechanisms. It has been a long-standing interest and effort
to study the biological processes and metabolic pathways of
natural cells and organisms. Grateful to the accumulating
knowledge, nowadays we are able to create a cell with a min-
imal genome by removing non-essential biological processes
and metabolic pathways [18]. These cells constitute an engi-
neering platform where designer cells with desired functions
can be engineered by adding specific metabolic pathways and
genetic circuits to the minimal genome. For the first proof-
of-concept, in 2016, Hutchison et al. reported a synthetic
Mycoplasma mycoides genome from the JCVI-syn3.0 project,
which represents an important milestone in the synthetic biol-
ogy field. Aimed to build a synthetic minimal genome, they
maximally deleted the non-essential genomic DNA from the
original genome, and the synthesized genome only has a size
of 531 Kb and contains 473 genes [18]. To our knowledge, this
is the first and only completed synthetic chassis cell with a
quasi-essential genome.Alter genetic encoding/decoding rules
Genome writing does not have to follow the existing rules of
genetic encoding and decoding, thereby holding the potential
to create new life forms that do not exist in nature [19].
Although different organisms differ vastly in many aspects,
their genomes are encoded by the same four nucleotides, and
their proteins are assembled with the same 20 types of amino
acids. Synthetic organisms, on the other hand, may be
designed to incorporate additional types of nucleotides into
their genomes and non-canonical amino acids into their pro-
teins. By altering the codon rules and using modified tRNAs,
new proteins containing non-canonical amino acids can be
obtained. In 2013, Lajoie et al. replaced the TAG stop codons
with the TAA stop codons and reassigned TAG codon for
non-canonical amino acids like p-acetylphenylalanine in
Escherichia coli MG1655 [20]. In 2017, Zhang et al. incorpo-
rated unnatural base pairs into DNA and non-canonical
amino acids into green fluorescence protein using specific
tRNAs [19]. These studies have greatly expanded the repertoire
for central dogma including DNA replication, transcription,
Wang Y et al / Progress of Genome Writing 13and translation, thereby paving the way for creating a variety
of artificial organisms with special features.
Build artificial life with synthetic/chimeric genome
De novo design of an artificial genome holds promise for gain-
ing novel insights into cellular processes and metabolic path-
ways. In order to make an artificial cell with a functional
synthetic genome, several rounds of the design-build-test
(DBT) processes are needed. The DBT processes may help to
discover and understand the mechanisms and processes that
are otherwise not accessible with traditional means. Different
organisms vary greatly in their composition of genomes and
proteomes, as well as their metabolic processes and cellular
functions. However, they do share many common features in
basic cellular processes [17]. For example, all cells, albeit from
different organisms, have common processes for energy meta-
bolism, DNA replication, DDR, RNA transcription, protein
translation, etc. However, in different cells or organisms, these
processes are likely regulated by different genes and proteins,
which often share sequence homologies. De novo synthesis
and assembly of different genomes will help gain insights into
the conservation and divergence, as well as the crosstalk
between genetic elements and proteins from different
organisms.
In recent years, several genomic DNA synthetic projects
have been completed or underway, including viral, prokary-
otic, eukaryotic, and mammalian genome (Table 1)
[8,18,21,22,24–29]. Among them, the humanized mouse
project represents an important advance. Researchers used
human immunoglobulin loci to replace the corresponding
immunoglobulin loci in the mouse genome. The obtained
humanized mice have a functional immune system and are able
to produce humanized antibodies [23,24].
Advances in genome writing drive the birth of
commercial applications
Cellular processes such as metabolism are largely controlled by
genome. Genome writing technologies can change genomeTable 1 Summary of synthetic genomic DNA projects
No. Year Species Cla
1 2002 Poliovirus Viru
2 2010 Mycoplasma mycoides Bac
3 2011 Saccharomyces cerevisiae Fun
4 2014 Homo sapiens Ma
5 2014 Homo sapiens Ma
6 2016 Mycoplasma mycoides Bac
7 2017 Saccharomyces cerevisiae Fun
8 2017 Saccharomyces cerevisiae Fun
9 2017 Saccharomyces cerevisiae Fun
10 2017 Saccharomyces cerevisiae Fun
11 2017 Saccharomyces cerevisiae Funinformation at a large or small scale, which enables
the design and engineer of organism catering to specific
applications.
Here, we list some examples on how to use genome writing
technologies to develop useful products or therapeutics
(Figure 2). (1) The synthetic cell with a minimal genome and
customized metabolism pathway(s) [18]. The synthetic cell is
designed to only possess necessary fundamental metabolism
in order to reduce nutrient loss and promote the synthetic effi-
ciency of target products. For different applications, relevant
metabolic pathway(s) can be incorporated into the genome
of these synthetic cells. For example, to produce biofuels, etha-
nol biosynthesis pathway can be added [30,31]; to produce
antimalarial pharmaceutical compounds, artemisinin biosyn-
thesis pathway may be added [32]. (2) Gene therapy and cell
therapy [33–36]. Stem cells are isolated from the patient with
genetic defects. Gene editing is then employed to correct
genetic mutations in vitro. Finally, the genetically-corrected
cells are transplanted back to the patient to cure the disease.
In addition to repair defective genes, more sophisticated gen-
ome manipulations, e.g., incorporating genetic circuits, has
been used for cancer immunotherapy. In 2017, Nissim et al.
reported using a genetic AND logic circuit to direct immune
cells to specifically target and kill cancer cells [36]. (3) Genera-
tion of humanized animal models [23,24,37]. Using genome
editing, we can humanize animal genomes for different appli-
cations. For example, humanized mice are used to develop
humanized antibodies. Humanized pigs may offer a solution
to solve worldwide shortage of organ donors by providing
immune-compatible pig organs for human transplantations
in the future. (4) High-throughput functional study of human
genetic variants [38,39]. The costs of genomic sequencing are
dropping rapidly, and vast amounts of genomic data are pro-
duced. However, due to the lack of annotations of the vast
majority of human variants, it is difficult to extract useful
information from personal genome sequencing data. The rapid
development of genome writing technologies has led to a sig-
nificant reduction in the cost of large-scale DNA synthesis.
Using techniques such as deep mutational scanning combined
with high-throughput sequencing, we are able to perform high-
throughput functional studies of human variants [38]. This willssification Project name Scale Ref.
s N/A 7.5 Kb [21]
teria JCVI-syn1.0 1.08 Mb [22]
gi Sc2.0_synIX-R 91 Kb [8]
Sc2.0_semi-synVI-L 30 Kb [8]
mmal N/A 1.42 Mb [23]
mmal N/A 2.7 Mb [24]
teria JCVI-syn2.0 576 Kb [18]
JCVI-syn3.0 531 Kb [18]
gi Sc2.0_synXII 976 Kb [25]
gi Sc2.0_synVI 242 Kb [26]
gi Sc2.0_synII 770 Kb [27]
gi Sc2.0_synX 707 Kb [28]
gi Sc2.0_synV 536 Kb [29]
Figure 2 Examples of genome writing based applications
A. Designer cells with customized metabolism. A pre-built cell with the minimal genome can be used to add relevant metabolic pathway(s)
and genetic circuits for different applications. B. Making humanized animal models. Humanized mice can be used for therapeutic
antibody production and humanized pigs can be used for organ transplantation. C. Using genetically-engineered cells for human disease
treatment. First, stem cells or precursors are isolated from the patient, followed by genetic manipulation in vitro. Subsequently, those
engineered cells are reinfused into the patient to cure disease. D. Schematic diagram of deep mutational scanning process. A synthetic
mutant library is constructed and packaged as viruses. After transduction, positively-transduced cells are treated by a gene-specific
functional assay. This assay should be able to separate the cells infected with the pathogenic variants from the cells infected with the
neutral variants. Through fluorescence-activated cell sorting, those cells can be separated into two groups. One group of cells is primarily
infected with pathogenic variants, while the other group of cells is predominantly infected with neutral variants. Later, variants are
amplified from both groups of cells and then subjected to next-generation sequencing. Mutational effects are evaluated based on
complicated mathematical models. All variants will have evaluation scores which can be used to make a visual diagram, e.g., heatmap.
14 Genomics Proteomics Bioinformatics 16 (2018) 10–16
Wang Y et al / Progress of Genome Writing 15greatly advance the development of personal genome sequenc-
ing projects and facilitate precision medicine applications.
Challenges and prospects
Since the beginning of the 21st century, rapid progresses have
been made in the synthetic biology field. However, there still
remain many challenges, which require continued investments
and efforts.
(1) Further understanding of the cellular/biological pro-
cesses and metabolism pathways is needed. Understanding of
the natural biological processes and metabolism pathways is
a prerequisite to the development of any new synthetic biology
designs and applications. There are more than eight million
types of different species living on Earth. Among them, many
are complex multicellular organisms that have a multitude of
cell types with different compositions and functions. These
cells share common fundamental metabolisms, but also differ
in the specific metabolic pathway(s). What are the factors
involved? What are the relations between these factors? Lots
of work needs to be done to answer these questions.
(2) Technically, the cost of genome synthesis needs to be
reduced and the efficiency increased. At present, implementing
a large-scale synthetic genomic project is still costly and time-
consuming. For small-scale genome editing, the current tech-
niques are still inefficient in HDR-based precision editing.
Genome editing based on the customizable nucleases relies
on the intrinsic cellular DNA DSB repair mechanisms. Due
to the difficulties of precisely controlling the DNA repair pro-
cesses, the efficiency for error-free repair is inherently low. In
addition, the off-target effects are also an important concern
that needs to be further addressed.
(3) There are bioethics and biosafety concerns [40,41]. Syn-
thetic biology has made it easy to synthesize human-animal
chimeric genomes. A human-animal chimera can be made by
incorporating large amounts of human genomic fragments into
an animal genome, or vice versa. As time goes by, it will
become increasingly difficult to define whether such kinds of
chimeras are human or animal. In addition, it has been
reported that synthetic viruses have the same infectivity com-
pared to their natural counterparts [21]. Criminals or terrorists
may use synthetic pathogens to engage in criminal activities
that endanger public safety. Therefore, we must take measures
to ensure that synthetic biology technologies are not indiscrim-
inately used to prepare toxic, infectious, and other harmful
organisms or biological materials.
In general, synthetic biology marks a new era in the biolog-
ical field. Different from physics and chemistry, there do not
exist simple and clear disciplines to follow in biology area
when developing applications. Basically, all species are black
boxes with extremely complex structures and functions. Fully
understanding the laws is the premise of all applications for
every discipline. In the past century, the biological studies have
undergone a rapid development, which tremendously pro-
motes our understanding of organismal heredity and develop-
ment. All these have laid an important foundation for the birth
of synthetic biology. In the future, with a combination of gen-
ome writing technologies, genetic circuit technologies, new
genetic encoding and decoding technologies, etc., we might
be able to create new species or resuscitate extinct species
according to human needs.Competing interests
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